In patients with solid carcinomas, NanOlogy™ has demonstrated that local administration of patented submicron particles continuously exposes primary tumors to … Continued

Highlights of the presentation by Dr. Neil Sharma, President, Parkview Cancer Institute; Director of Advanced Interventional Endoscopy and Endoscopic Oncology … Continued

Slide 1 Pancreatic mucinous cystic lesions have significant potential for malignant transformation1; delivery of SPP as a direct intratumoral injection … Continued

A novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer. A Prospective Safety, … Continued

Interim data from both clinical trials presented at the 2019 American College of Gastroenterology (ACG) Conference in San Antonio November … Continued

Preclinical Study Demonstrated Inhaled NanoPac Shows Prolonged Retention and Limited Systemic Exposure FORT WORTH/DALLAS, (October 30, 2018) — NanOlogy, a clinical-stage … Continued

Soria investigational drug provides evidence of actinic keratosis (AK) lesion reduction without the local irritation of approved topical AK treatment … Continued

Preliminary Data from Both Trials Show NanoPac Well-Tolerated via Intratumoral and Intracystic Injection FORT WORTH/DALLAS, (August 8, 2018) — NanOlogy LLC, … Continued

Intratumoral injection of three concentrations of NanoPac successfully completed across a total of 9 patients Highest concentration of NanoPac continues … Continued

Background: NanoPac® is patented submicron particle paclitaxel in stable powder form without coating or carrier agents. In a previous PK study, … Continued